New Clinical Data Presented at DDW 2025 Shows mBIOTA Elemental™ Reduces Methane-Producing Archaea in IMO Patients

mBIOTA Labs continues to push the boundaries of medical nutrition with new clinical data demonstrating that its flagship product, mBIOTA Elemental™, not only supports the management of bacterial overgrowth but also significantly reduces methane-producing archaea, specifically Methanobrevibacter smithii, in patients with Intestinal Methanogen Overgrowth (IMO).

The findings were presented at Digestive Disease Week (DDW) 2025 in a featured oral presentation titled “Reduction Of Breath Methane Levels Correlates With Fecal Abundance Of Methanobrevibacter Smithii Following Two-Weeks Of Exclusive Oral Elemental Diet.” Full details are available via Business Wire.

Study Overview

Participants with IMO followed a 2-week exclusive mBIOTA Elemental™ protocol, followed by 2 weeks of food reintroduction. Daily breath methane levels and stool samples were collected and analyzed using digital PCR. Results showed:

• M. smithii was detected in 61% of participants at baseline.
• By study end, 92% of participants had a decrease or complete elimination of M. smithii.

These results offer the strongest evidence to date that mBIOTA Elemental™ can effectively modulate the gut microbiome beyond just bacteria, targeting hard-to-treat archaea that are often linked with persistent gastrointestinal symptoms, including chronic constipation.

Expert Insights

Dr. Ali Rezaie, mBIOTA Labs medical advisor and a leading expert in the gut microbiome, emphasized the significance of the findings:

“The gut microbiome includes more than just bacteria. Archaea like M. smithii can be key drivers of GI symptoms. These results suggest we may have a new nutritional tool to target methane-producing organisms directly.”

CEO Nicola Wodlinger added:

“This research reinforces our commitment to delivering science-backed, patient-accessible tools for managing root causes of GI dysfunction. It’s an important step forward for helping IMO patients find sustainable relief.”

A Step Forward in Gut Health Innovation

mBIOTA Elemental™ has already gained attention for its 100% patient compliance rate and high efficacy in SIBO and IMO treatment, due in part to its unique palatable formulation using proprietary Amino Taste Modification Technology (ATMT). With this new evidence, mBIOTA Labs continues to establish itself as a leader in functional medical nutrition targeting complex GI conditions.

To learn more about this study or explore mBIOTA’s clinical offerings, visit www.mbiota.com/clinicaldata